News for Genting Singapore Ltd (36T.MU)

KUALA LUMPUR (Jan 10): Few may pay much attention to Genting Bhd's life-sciences division. However, the biotech unit could be reaping its fruits via listing, after it merges with NASDAQ-listed GX Acquisition Corp to form a special purpose acquisition company (SPAC) in an attempt to create a publicly-listed leader in allogeneic cellular therapy. This would also represent the first major monetisation in Genting’s life-sciences division.